EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis

Mi Na Kim iD, Geun U Park, Seng Chan You, Jae Seung Lee iD, Hye Won Lee iD, Beom Kyung Kim iD, Seung Up Kim iD, Jun Yong Park, Do Young Kim iD, Sang Hoon Ahn iD

Journal of Gastroenterology and Hepatology · 2025

DOI: 10.1111/jgh.70078 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Mi Na Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Gastrointestinal Hemorrhage, Aspirin, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Research Supporting Program of The Korean Association for the Study of the Liver and The Korean Liver Foundation, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The use of aspirin in hepatocellular carcinoma (HCC) prevention and the risk of gastrointestinal (GI) bleeding is still uncertain in patients with hepatitis B virus (HBV)‐related cirrhosis. We investigated the association between aspirin use and the risks of HCC and GI bleeding in patients with HBV‐related cirrhosis.

Methods

We conducted a 3‐year landmark analysis using nationwide cohort data from the National Health Insurance Service of South Korea. Patients diagnosed with compensated HBV‐related cirrhosis in 2005–2017 were included. Patients who were prescribed aspirin for at least 90 days consecutively during the 3‐year exposure period were classified as the aspirin‐treated group. The risks of HCC and GI bleeding were estimated in a cohort matched by propensity scores.

Results

During a median of 7.6 years of follow‐up, the 10‐year cumulative incidence of HCC was 41.8% among aspirin users ( n = 608) and 46.5% among nonusers ( n = 2432) ( p = 0.033). The aspirin‐treated group showed a significantly lower risk of HCC than the untreated group (adjusted hazard ratio [aHR] = 0.84, 95% confidence interval [CI] = 0.73–0.96; p = 0.013). The 10‐year cumulative incidence of GI bleeding was 29.5% among aspirin users and 24.0% among nonusers ( p = 0.016). The aspirin‐treated group showed a significantly higher risk of GI bleeding than the untreated group (aHR = 1.20, 95% CI = 1.02–1.42; p = 0.029).

Conclusions

In patients with HBV‐related cirrhosis, the aspirin‐treated group showed a significantly lower risk of HCC than the untreated group, whereas the risk of GI bleeding was significantly higher in the aspirin‐treated group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal HemorrhageAspirinCarcinoma, HepatocellularLiver NeoplasmsLiver CirrhosisHepatitis BHumansMaleFemaleMiddle AgedRepublic of KoreaIncidenceAgedRisk FactorsAdultCohort StudiesFollow-Up Studies

Stichwörter der Autor:innen

aspirinchronic hepatitis Bcirrhosisgastrointestinal bleedinghepatocellular carcinoma

Substanzen

Aspirin

Autor:innen und Institutionen

  • Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Yonsei Liver Center, Severance Hospital, Seoul, Republic of Korea.
  • Clinical and Translational Hepatology Laboratory, Seongnam, Republic of Korea.
  • Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Mi Na Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn

Förderung

  • Research Supporting Program of The Korean Association for the Study of the Liver and The Korean Liver Foundation
  • National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency

Zitieren

APA

Kim, M. N., Park, G. U., You, S. C., Lee, J. S., Lee, H. W., Kim, B. K., Kim, S. U., Park, J. Y., Kim, D. Y., & Ahn, S. H. (2025). Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70078

Vancouver

Kim MN, Park GU, You SC, Lee JS, Lee HW, Kim BK, et al. Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.70078

BibTeX
@article{Kim2025,
  author = {Kim, Mi Na and Park, Geun U and You, Seng Chan and Lee, Jae Seung and Lee, Hye Won and Kim, Beom Kyung and Kim, Seung Up and Park, Jun Yong and Kim, Do Young and Ahn, Sang Hoon},
  title = {Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2025},
  doi = {10.1111/jgh.70078}
}
Kostenlos starten →